Cefpodoxime Proxetil
An oral third-generation cephalosporin prodrug that is de-esterified in the intestinal wall to the active compound cefpodoxime. It provides broad-spectrum activity against common respiratory pathogens and is used for ear, throat, sinus, and urinary tract infections. Food enhances its absorption, and it should be taken with meals for optimal effect.
分子量
557.6000 g/mol
LogP
0.60
TPSA
235.00 Ų
Lipinski 五规则
不符合
作用机制
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
二维结构
Cite this structure
Embed this structure
SMILES
COCC1=C(C(=O)OC(C)OC(=O)OC(C)C)N2C(=O)[C@@H](NC(=O)/C(=N\OC)c3csc(N)n3)[C@H]2SC1
InChI
InChI=1S/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h8-10,14,18H,6-7H2,1-5H3,(H2,22,23)(H,24,27)/b25-13-/t10?,14-,18-/m1/s1
Molecular Formula
C21H27N5O9S2
HBD / HBA
2 / 14
可旋转键数
13
重原子数
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
An oral third-generation cephalosporin prodrug that is de-esterified in the intestinal wall to the active compound cefpodoxime. It provides broad-spectrum activity against common respiratory pathogens and is used for ear, throat, sinus, and urinary tract infections. Food enhances its absorption, and it should be taken with meals for optimal effect.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefpodoxime Proxetil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201016. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6526396. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefpodoxime-proxetil"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefpodoxime-proxetil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefpodoxime-proxetil/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefpodoxime-proxetil/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefpodoxime-proxetil"></drugfyi-drug>